Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 3 people enrolled
- Started
- 20 Mar 2024
- Ended
- 10 Sept 2024
- Type of study
- Observational
- Record updated
- 10 July 2025
- Why it stopped
- Slow accrual.
Who can take part
- Age
- 35 years to 120 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who cannot take part
- Prior prostate biopsy
- Prior radiotherapy or surgery for prostate cancer
- Prior or ongoing hormonal therapy or chemotherapy (e.g., docetaxel) for prostate cancer
- Participants unwilling or unable to undergo MRI, including participants with contraindications to MRI
- Participants unwilling or unable to undergo biopsy, including participants with contraindications to biopsy
Other criteria
- INCLUSION CRITERIA:
- Age >35 years
- Men self-identified as being of African Ancestry
- Elevated serum prostate specific antigen of >=3ng/ml and/or positive digital rectal examination and/or strong family history of prostate cancer (at least 1 first or second degree male relative)
- ECOG performance status <=2
- Ability of participant to understand and the willingness to sign a written informed consent document
- Must be co-enrolled in protocols 16-C-0010 and/or 18-C-0017
Where in United States
- National Institutes of Health Clinical CenterBethesda, United States
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Prostate cancer (PCa) is one of the most common cancers in American men; it is a leading cause of death. Men of African ancestry have a higher rate of prostate cancer, and a higher likelihood of death, compared to men of European ancestry. The reasons for these higher rates are not known; they may include genetic and environmental factors. Better screening methods are needed.
Objective:
To test an imaging technology called multiparametric magnetic resonance imaging (mpMRI) for detecting prostate cancer in men of African ancestry.
Eligibility:
Men of African ancestry aged 35 years or older with prostate cancer and/or a strong family history of prostate cancer.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests.
Participants will have an mpMRI. They will lie on a narrow bed that slides into a large cylinder. They will lie still for about 45 minutes. They will hear loud noises during the scan; they may wear earplugs or headphones to muffle the sound. Some participants may have a dye injected into a vein.
If the scan indicates participants risk of prostate cancer is medium or high, they will have a biopsy: The area will be numbed, and samples of tissue will be removed from the prostate. The biopsy will be done within 6 months.
If the scan indicates participants risk of prostate cancer is low, they will not have a biopsy.
All participants will be followed for 5 years. They and/or their local doctors will be contacted once a year for follow-up. Additional mpMRIs may be recommended.
The group in the trial
- Cohort 1
Participants of African Ancestry with elevated serum prostate specific antigen of (Bullet)3ng/ml or positive digital rectal examination or strong family history.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
- Record updated
- 10 July 2025